Drug Profile
Benralizumab - AstraZeneca/Kyowa Kirin
Alternative Names: Benra; Benralizumab - AstraZeneca/Kyowa Hakko Kirin; Benralizumab - Kyowa-Hakko/AstraZeneca; BIW-8405; BIW-8405-IL-5R; Fasenra; KHK-4563; MEDI-563Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator BioWa
- Developer AstraZeneca; Kyowa Hakko; Kyowa Kirin; McMaster University; MedImmune; National Jewish Medical and Research Center
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma
- Preregistration Nasal polyps
- Phase III Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Hypereosinophilic syndrome
- Phase II Atopic dermatitis; Rhinosinusitis
- No development reported Skin disorders
- Discontinued Bronchiectasis; Bullous pemphigoid; Chronic urticaria; Eosinophilic gastroenteritis; Eosinophilic oesophagitis
Most Recent Events
- 11 Apr 2024 The US FDA approves benralizumab for Asthma (Adjunctive treatment, In children) (aged 6 to 11) (SC)
- 26 Feb 2024 Efficacy data from the phase III MANDARA trial in Churg-Strauss syndrome released by AstraZeneca
- 13 Feb 2024 AstraZeneca completes phase-III clinical trials in Eosinophilic gastroenteritis (In adolescents, In adults, In children) in USA, Vietnam, Ukraine, Mexico, Japan, Italy, France, China, Canada, Brazil, Australia (SC) (NCT05251909)